Current stock page

Stock Analysis

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Protagonist Therapeutics, Inc. (PTGX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PTGX Stock Analysis Summary

Protagonist Therapeutics, Inc. (PTGX) currently has an AIQ Score of 73/100, indicating a bullish setup. Quality is the strongest factor at 81/100. Risk is the weakest current factor at 70/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

PTGX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$130.95
AIQ Score73/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$8.69B
P/E Ratio (TTM)25.39
Forward P/E—
EPS (Q3 FY2026)$3.32
Revenue (Q3 FY2026)$274.41M
Dividend Yield (TTM)0.00%
Beta0.91
Volume759.92K
52-week range$77.00-$160.81
RSI 1438.86
50-Day SMA$140.30
200-Day SMA$119.29
Analyst Price Target$176.80
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

PTGXProtagonist Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$130.95−$3.43 (−2.55%)

Latest quote

  • Momentum
    70
  • Value
    72
  • Quality
    81
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

PTGX Stock Analysis Summary

Protagonist Therapeutics, Inc. (PTGX) currently has an AIQ Score of 73/100, indicating a bullish setup. Quality is the strongest factor at 81/100. Risk resilience is the weakest current factor at 70/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, PTGX has AIQ Score of 73/100 with Quality base of 81/100 and fading Risk resilience at 70/100. Wait for component alignment before adding exposure.

Healthcare · -2.55% stock move · PTGX classified in Biotechnology.

Current Evidence

BullishPTGX is in a bullish AIQ regime; Quality is the strongest visible factor at 81/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PTGX Bullish or Bearish Right Now?

PTGX currently has a bullish overall setup. Quality is the strongest factor at 81/100, while Momentum is weakest at 70/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 81/100.
  • - Momentum is constructive at 70/100.
  • - Risk Resilience is supportive at 70/100.
  • - Analyst target implies +35.01% upside from the latest quote.
Bear Case
  • - Technical consensus has more sell votes than buy votes (35 vs 7).

Current Consensus

PTGX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. PTGX's 14-day RSI is 38.86, which places the stock in a weaker momentum range. PTGX's beta is 0.91, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in PTGX?

The largest recent change in PTGX is Momentum moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-3.0
Momentum
-8.0
Quality
-1.0
Risk
+1.0

What Would Change the PTGX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PTGX Decision Framework

Public evidence layers, setup checks, and risk context for Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis

Protagonist Therapeutics, Inc. has an AIQ Score of 73/100 in a Bullish regime. Quality is strongest at 81/100. Beta is 0.91, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPTGX is in a Bullish AIQ regime with score 73/100.
Signal ConflictThe primary conflict is that quality leads at 81/100 while momentum lags at 70/100.
Factor EvidenceMomentum 70/100 · Value 72/100 · Quality 81/100 · Risk 70/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 81/100.

TimingPass

Momentum is 70/100 and RSI (14) is 38.9.

Regime fitPass

PTGX is in a Bullish regime at 73/100.

Risk controlPass

Risk factor is 70/100 with beta 0.91 and annual volatility 40.11%.

ConflictPass

Current conflict: quality leads at 81/100 while momentum lags at 70/100.

AIQ Score
73/100
Price
$130.95
Beta
0.91
RSI (14)
38.9

PTGX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PTGX Fundamentals

PTGX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$274.41M
Net income
$220.02M
Free cash flow
-$23.46M
View full PTGX fundamental analysis

PTGX Technical Analysis

PTGX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
38.86
Price vs SMA-50
-6.66%
View full PTGX technical analysis

PTGX Stock Catalysts

Track PTGX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$176.80
News items
4
View PTGX earnings and stock catalysts

PTGX Dividend Analysis

PTGX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PTGX dividend history and analysis

PTGX Financial Data

PTGX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$274.41M
EPS
$3.32
Periods
8
View PTGX financials

PTGX Risk Analysis

PTGX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.91
Risk score
70/100
1Y volatility
40.11%
View PTGX risk analysis

PTGX Stock News

PTGX stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read PTGX stock news

PTGX vs Biotechnology Peers

Current peer cohort: PTGX · PVLA · QURE · RAPP · RCUS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PTGX
Current stock
73/10072/10070/10070/1001.2440.11%Current
PVLA
Palvella Therapeutics, Inc.
70/100—84/10047/1001.1284.47%PTGX vs PVLA
QURE
uniQure N.V.
39/10038/10041/10031/1000.39132.25%PTGX vs QURE
RAPP
Rapport Therapeutics, Inc. Common Stock
43/10042/10033/10039/1000.3562.34%PTGX vs RAPP
RCUS
Arcus Biosciences, Inc.
39/10043/10034/10042/1000.0562.65%PTGX vs RCUS
Pairwise Compare links: PVLA · QURE · RAPP · RCUSPTGX vs PVLAPTGX vs QUREPTGX vs RAPPPTGX vs RCUSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PTGX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PTGX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
25.39
As of Nov 13, 2026
Revenue growth
5723.64%
Gross margin
99.73%
Current debt / equity
0.01
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$274.41M
Quarter net income
$220.02M
Quarter free cash flow
-$23.46M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
38.86
MACD
-1.83

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
70/100
Beta
0.91
Annual volatility
40.11%
Max drawdown
-18.83%

PTGX Stock FAQ

What is PTGX stock price today?

Protagonist Therapeutics, Inc.'s current stock price is $130.95. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PTGX bullish or bearish right now?

PTGX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PTGX's market cap?

PTGX's market cap is $8.69B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PTGX's current P/E ratio?

PTGX's current P/E ratio is 25.39 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PTGX's RSI?

PTGX's 14-day RSI is 38.86 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PTGX above its 50-day and 200-day moving averages?

PTGX is -6.66% from its 50-day SMA and 9.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PTGX's next earnings date?

PTGX's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PTGX pay a dividend?

PTGX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.